Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Mehta

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 27, 2010
Therapeutic goals in the treatment of Fabry diseaseAtul Mehta, Michael L West, Guillem Pintos-Morell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 22, 2010
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literatureOlivier Lidove, Michael L West, Guillem Pintos-Morell, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
Brain : a Journal of Neurology|February 28, 2014
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cellsAlisdair McNeill, Joana Magalhaes, Chengguo Shen, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Stem Cell Research|November 18, 2022
Human induced pluripotent stem cells generated from STING-associated vasculopathy with onset in infancy (SAVI) patients with a heterozygous mutation in the STING geneAtul Mehta, Quan Yu, Yangtengyu Liu, et al.
Neurochemistry International|October 27, 2012
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damageMichael W J Cleeter, Kai-Yin Chau, Caroline Gluck, et al.
Molecular Genetics and Metabolism|May 13, 2017
Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry diseaseMaarten Arends, Frits A Wijburg, Christoph Wanner, et al.
European Journal of Haematology|December 10, 2019
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosisFaye A Sharpley, Dunnya De-Silva, Shameem Mahmood, et al.
Orphanet Journal of Rare Diseases|November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesDominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 27, 2010
Therapeutic goals in the treatment of Fabry diseaseAtul Mehta, Michael L West, Guillem Pintos-Morell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 22, 2010
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literatureOlivier Lidove, Michael L West, Guillem Pintos-Morell, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
Brain : a Journal of Neurology|February 28, 2014
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cellsAlisdair McNeill, Joana Magalhaes, Chengguo Shen, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Stem Cell Research|November 18, 2022
Human induced pluripotent stem cells generated from STING-associated vasculopathy with onset in infancy (SAVI) patients with a heterozygous mutation in the STING geneAtul Mehta, Quan Yu, Yangtengyu Liu, et al.
Neurochemistry International|October 27, 2012
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damageMichael W J Cleeter, Kai-Yin Chau, Caroline Gluck, et al.
Molecular Genetics and Metabolism|May 13, 2017
Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry diseaseMaarten Arends, Frits A Wijburg, Christoph Wanner, et al.
European Journal of Haematology|December 10, 2019
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosisFaye A Sharpley, Dunnya De-Silva, Shameem Mahmood, et al.
Orphanet Journal of Rare Diseases|November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesDominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Pageof 15